Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewI-CBP 112
Description: Selective CBP/p300 BRD inhibitor
Chemical Name: 1-[7-(3,4-Dimethoxyphenyl)-9-[[(3S)-1-methylpiperidin-3-yl]methoxy]-2,3,4,5-tetrahydro-1,4-benzoxazepin-4-yl]propan-1-one
Purity: ≥98% (HPLC)
Biological Activity for I-CBP 112
I-CBP 112 is a CBP/p300 bromodomain inhibitor (IC50 values are 0.142-0.17 and 0.625 μM for CBP and p300 respectively). Selective for CBP and p300 over ATAD2, BAZ2B, BRD2(2), BRD4(1), PB1(5), PCAF, PHIP(2) and TIF1α bromodomains in a BLI assay. Accelerates FRAP recovery in cells at a concentration of 1 μM.
Licensing Information
This probe is supplied in conjunction with the Structural Genomics Consortium. For further characterization details, please visit the I-CBP 112 probe summary on the SGC website.
External Portal Information for I-CBP 112
Chemicalprobes.org is a portal that offers independent guidance on the selection and/or application of small molecules for research. The use of I-CBP 112 is reviewed on the chemical probes website.
Technical Data for I-CBP 112
| M. Wt | 468.59 |
| Formula | C27H36N2O5 |
| Storage | Desiccate at RT |
| Purity | ≥98% (HPLC) |
| CAS Number | 1640282-31-0 |
| PubChem ID | 90488984 |
| InChI Key | YKNAKDFZAWQEEO-IBGZPJMESA-N |
| Smiles | COC(C(OC)=C1)=CC=C1C2=CC(OC[C@H]3CCCN(C)C3)=C(OCCN(C(CC)=O)C4)C4=C2 |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Product Datasheets for I-CBP 112
References for I-CBP 112
References are publications that support the biological activity of the product.
Gallenkamp et al (2014) Bromodomains and their pharmacological inhibitors. ChemMedChem 9 438 PMID: 24497428
View Related Products by Target
View Related Products by Product Action
Keywords: I-CBP 112, I-CBP 112 supplier, I-CBP112, CREBBP, EP300, bromodomains, selective, inhibitors, inhibits, chemical, probes, SGC, epigenetics, structural, genomics, consortium, Bromodomains, Histone, Acetyltransferases, 4891, Tocris Bioscience
Citations for I-CBP 112
Citations are publications that use Tocris products.
Currently there are no citations for I-CBP 112.
Reviews for I-CBP 112
There are currently no reviews for this product. Be the first to review I-CBP 112 and earn rewards!
Have you used I-CBP 112?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Stem Cell Research Product Guide
This product guide provides a background to the use of small molecules in stem cell research and lists over 200 products for use in:
- Self-renewal and Maintenance
- Differentiation
- Reprogramming
- Organoid Generation
- GMP and Ancillary Material Grade Products
Epigenetics Scientific Review
Written by Susanne Müller-Knapp and Peter J. Brown, this review gives an overview of the development of chemical probes for epigenetic targets, as well as the impact of these tool compounds being made available to the scientific community. In addition, their biological effects are also discussed. Epigenetic compounds available from Tocris are listed.
Epigenetics in Cancer Poster
This poster summarizes the main epigenetic targets in cancer. The dysregulation of epigenetic modifications has been shown to result in oncogenesis and cancer progression. Unlike genetic mutations, epigenetic alterations are considered to be reversible and thus make promising therapeutic targets.
Rheumatoid Arthritis Poster
Rheumatoid arthritis (RA) is a chronic destructive inflammatory autoimmune disease that results from a breakdown in immune tolerance, for reasons that are as yet unknown. This poster summarizes the pathology of RA and the inflammatory processes involved, as well as describing some of the epigenetic modifications associated with the disease and the potential for targeting these changes in the discovery of new treatments.